Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.38 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12487339 | 0.85 | CNR2 (0.45) | ELANEPOLBCNR2HTR7PTGER2 | |
| SCHEMBL9893103 | 0.83 | NSD2 (0.45) | GRM2KCNA5 | |
| SCHEMBL16480373 | 0.80 | POLB (0.46) | ELANEPOLBCNR2HTR7CYP11B2 | |
| SCHEMBL9893023 | 0.80 | PER2 (0.46) | CNR2HTR7PTGER2PTGER3PTGDR | |
| SCHEMBL9893157 | 0.80 | PTGER2 (0.42) | PTGER2PTGER4PTGER3PTGDR | |
| SCHEMBL9892975 | 0.80 | PTGER2 (0.44) | PTGER2PTGER4PTGER3PTGDRP2RX7 | |
| SCHEMBL9892976 | 0.78 | PTGER2 (0.41) | PTGER2PTGER4PTGER3PTGDR | |
| SCHEMBL9892982 | 0.77 | PTGS2 (0.44) | CNR2PTGER2PTGER4PTGER3PTGDR | |
| SCHEMBL9892985 | 0.77 | PTGER2 (0.48) | CNR2PTGER2PTGER3GRM2PTGDR | |
| SCHEMBL9891733 | 0.77 | CNR2 (0.47) | ELANEPOLBCNR2HTR7PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2384320-B1 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ELANE 2784/4885POLB 2879/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.